IFM/DFCI 2009 Lénalidomide bortézomib et dexaméthasone (VRD
IFM/DFCI 2009. Lénalidomide bortézomib et dexaméthasone (VRD) contre autogreffe. Objectifs et évaluations. L'objectif principal est de comparer la survie
IFM/DFCI 2009 Lénalidomide bortézomib et dexaméthasone (VRD
IFM/DFCI 2009. Lénalidomide bortézomib et dexaméthasone. (VRD) contre autogreffe. Type d'étude. Cet essai de phase 3 est mené dans plusieurs centres (voir
Traitement des patients de novo éligibles à lintensification
L'association VRD (= bortézomib lénalidomide et dexaméthasone) a également fait l'objet de 2 études de l'IFM(7
IMAJEM (IMAgerie JEune Myélome) (étude de radiologie adossée
IFM/DFCI 2009 (VRD vs autogreffe). diagnostic après 3 cycles d'induction VRD (bortézomib-Velcade®
MSAG Update - Bortezomib Lenalidomide and Dexamethasone (VRd)
MSAG Update: VRd for initial treatment of multiple myeloma – July 2020 weekly bortezomib schedule is used per the IFM 2009 or PETHEMA studies ...
Autologous stem cell transplantation for multiple myeloma: history
The BMT/CTN 0702 trial (left) and IFM/Dana-Farber Cancer. Institute [DFCI] 2009 trial (right). R: randomization VRD: bortezomib/lenalidomide/dexamethasone
Assessment report
28 mars 2019 PETHEMA GEM2012 IFM 2009
Does cure have a different meaning in multiple myeloma?
DTPACE; bortezomib dexamethasone
Revue concise
le traitement d'induction du myélome de diagnostic récent avec le protocole RVD (Revlimid +. Velcade + dexaméthasone). n L'IMWG publie une déclaration de
Rouault Élise
28 sept. 2020 VRd : Bortézomib Lénalidomide dexaméthasone ... VRD 13 MG/M² SOUS CUTANE SELON IFM/DFCI 2009)
IFM/DFCI 2009 Lénalidomide bortézomib et dexaméthasone (VRD
Nom et titre de l’étude IFM/DFCI 2009 Lénalidomide bortézomib et dexaméthasone (VRD) contre autogreffe Protocole de traitement et rythme des contrôles - Les patients reçoivent tous le même traitement d’induction VRD : 3 cures de 21 jours comprenant lénalidomide
Protocol - The New England Journal of Medicine
Lenalidomide+bortezomib+dexamethasone (RVD) q 21 days: 1 cycle Attal et al 2007) The aim of the IFM/DFCI 2009 protocol is therefore to compare the results (in terms of efficacy quality
FocusonmultiplemyelomaatASH2015 - Springer
(IFM/DFCI) 2009 trial are certainly noteworthy [1] In all 700 patients were randomized to two treatment arms Eight cycles of RVD (lenalidomide bortezomib dexamethasone) were compared with three cycles of RVD followed by high-dose chemotherapy and autol-ogous stem cell transplantation (ASCT) then followed by two consolidation cycles with RVD
Phase III SWOG-S0777 Trial of Bortezomib/ Lenalidomide
Jan 3 2016 · • Compare the efficacy of the 3-drug regimen of bortezomib lenalidomide and dexamethasone (RVd) to that of the 2-drug regimen Rd for the front-line treatment of MM • Consider the role of autologous stem cell transplant in the treatment of newly diagnosed MM in young patients
Hematology Updates in Myeloma - University of Virginia School
Apr 6 2022 · IFM 2009 PhIII NDMM transplant eligible RVd+ SCT is associated with a PFS benefit particularly for standard risk/low stage disease Attal et al lenalidomide bortezomib and dexamethasone with transplantation for myeloma NEJM 2017 Quads front-line for transplant eligible NDMM
What are the eligibility criteria for lenalidomide and dexamethasone transfusions?
- ? Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib and/or dexamethasone. ? Participants with platelet level <50,000/uL. Transfusion may not be used to meet platelet eligibility criteria
What is the recommended dose of lenalidomide?
- >500/uL and/or platelet count is 30,000/ L. If with 10 mg/day, lenalidomide will be held and resumed at a >500/uL and/or platelet count is 30,000/uL. If with 5 mg/day, lenalidomide will be held and resumed at a dose of 5 mg/day for 21 of 28 days when ANC > 500/uL and/or platelet count is > 30,000/uL.
Is erythropoietin allowed in lenalidomide maintenance?
- Erythropoietin is also allowed. 6.3.3 Concomitant therapy during Lenalidomide Maintenance Based on IFM 2005-02 study results which showed increased risk of thrombosis during the maintenance, thromboprophylaxis is required in maintenance for all patients: N-acetyl salicylic acid (100mg/d type aspirin or equivalent).
Does lenalidomide inhibit cyclooxygenase-2 expression in vitro?
- Lenalidomide inhibited the expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.
